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Abstract
Background: During the past two decades, methicillin-resistant Staphylococcus aureus (MRSA) has become increasingly
common as a source of nosocomial infections. Most studies of MRSA surveillance were performed during outbreaks, so
that results are not applicable to settings in which MRSA is endemic. This paper gives an overview of MRSA prevalence
in hospitals and other healthcare institutions in non-outbreak situations in Western Europe.
Methods: A keyword search was conducted in the Medline database (2000 through June 2010). Titles and abstracts
were screened to identify studies on MRSA prevalence in patients in non-outbreak situations in European healthcare
facilities. Each study was assessed using seven quality criteria (outcome definition, time unit, target population,
participants, observer bias, screening procedure, swabbing sites) and categorized as ‘good’, ‘fair’,o r‘poor’.
Results: 31 observational studies were included in the review. Four of the studies were of good quality.
Surveillance screening of MRSA was performed in long-term care (11 studies) and acute care (20 studies).
Prevalence rates varied over a wide range, from less than 1% to greater than 20%. Prevalence in the acute care
and long-term care settings was comparable. The prevalence of MRSA was expressed in various ways - the
percentage of MRSA among patients (range between 1% and 24%), the percentage of MRSA among S. aureus
isolates (range between 5% and 54%), and as the prevalence density (range between 0.4 and 4 MRSA cases per
1,000 patient days). The screening policy differed with respect to time points (on admission or during hospital
stay), selection criteria (all admissions or patients at high risk for MRSA) and anatomical sampling sites.
Conclusions: This review underlines the methodological differences between studies of MRSA surveillance. For
comparisons between different healthcare settings, surveillance methods and outcome calculations should be
standardized.
Background
Staphylococcus aureus (S. aureus) is a versatile human
pathogen that causes diseases ranging from relatively
mild infections of the skin and soft tissue to life-threaten-
ing sepsis [1]. The emergence of strains resistant to
methicillin and other antimicrobial agents has become a
major concern, especially in the hospital environment,
because of the higher mortality due to systemic methicil-
lin-resistant Staphylococcus aureus (MRSA) infections
[2]. Tiemersma et al. [3] have shown significant increases
in methicillin resistance in clinical strains of S. aureus
isolates between 1999 and 2002 in European countries,
particularly Belgium, Germany, Ireland, the Netherlands
and the United Kingdom. MRSA prevalence varied
widely, from < 1% in northern Europe to > 40% in south-
ern and western Europe [3]. As the prevalence of health-
care-associated infections (HAIs) caused by multidrug-
resistant organisms continues to increase [4], it seems
essential to prevent MRSA transmission and reduce the
n u m b e ro fM R S AH A I s .I ti sa l s oi m p o r t a n tf o rh e a l t h -
care workers that MRSA rates should be controlled, as a
recently published review has shown that the average
MRSA carrier rate in healthcare workers is 4.6%, and that
about 5.1% of these carriers had symptomatic MRSA
infections [5]. Although most MRSA infections in health-
care workers had a mild clinical course, some infections
tend to become chronic and can cause severe health pro-
blems. This may lead to long-term incapacity, as has
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workers’ compensation board [6].
For healthcare facilities, surveillance is an important and
generally accepted method to assess the incidence of infec-
tion due to multidrug-resistant bacteria and - if necessary -
to improve infection control measures [7]. Surveillance of
MRSA is a means of identifying colonized or infected
patients for whom specific control measures may be imple-
mented [8]. Surveillance may be passive, whereby labora-
tory results from clinical samples are monitored, or active,
whereby patients are actively screened for the carrier state
in order to identify the entire reservoir. The implementa-
tion of a program of active surveillance cultures beside
contact precautions is recommended by different national
guidelines as a way of preventing nosocomial transmission
of MRSA [9-12]. However, it is difficult to determine the
range of MRSA rates from existing literature [13], as sur-
veillance is primarily performed during outbreaks and gen-
eralization of these results is hampered, as the findings are
not applicable to non-outbreak situations [8]. Moreover, as
the recognition of MRSA as a hospital problem largely
depends on clinical samples or swabs taken either only on
admission or selectively for high risk patients, the true case
load of a hospital or a specific setting remains largely
unknown [14].
In the absence of comprehensive studies on the preva-
lence of MRSA, rates from MRSA surveillance in hospitals
have been transferred to other healthcare settings. How-
ever, it has been questioned whether control measures in
one setting can be generalized to other settings [9]. This
question applies to both epidemic and endemic MRSA
and also to specific settings, such as intensive care and
non-acute wards, where MRSA may have widely variable
transmission dynamics [8].
The aim of this review was to analyze the literature on
MRSA prevalence in endemic (non-outbreak) situations in
various clinical and long-term care (LTC) settings in
European countries. Special emphasis was given to the cal-
culation of MRSA outcomes and to MRSA screening
methods.
Methods
The search was conducted in the PubMed Medline
database (2000 through June 2010) and was limited to
articles in English or German. Inclusion and exclusion
criteria were established on the basis of an exploratory
search of the literature.
The search strategy used the keyword ‘MRSA’ combined
with a group of screening-related terms: ‘surveillance’
OR ‘infection control’ OR ‘prevalence’ AND ‘healthcare’.
Primary inclusion criteria were developed for the initial
selection of relevant articles, which were studies present-
ing MRSA prevalence rates. The initial search yielded 271
citations with an abstract. One of the authors (MD)
screened the titles and the abstracts, in order to identify
those that met the inclusion criteria, namely the preva-
lence of colonization or infection with MRSA in patients
or residents in clinical and nursing healthcare settings.
The exclusion criteria, with the number of excluded
abstracts, were as follows: community-associated (n = 64),
outbreaks (n = 41), study region outside Europe (n = 21),
and healthcare personnel as the sole study population (n =
6). Another 128 abstracts were excluded as they failed to
focus on MRSA prevalence. These included studies evalu-
ating control measures, and those assessing the efficacy of
special screening tests, or estimating MRSA transmission.
The search was repeated in combination with a group of
setting-related terms, namely ‘long-term care’ OR ‘nursing
home*’ OR ‘home care’ OR ‘mentally handicapped people’,
resulting in 65 additional abstracts of which 6 were
included. Finally, the reference lists of the retrieved articles
were checked for additional relevant studies, of which 15
were included. A total of 31 studies were included in the
analysis.
Studies were separated into clinical and LTC settings.
A data extraction form was developed to collect infor-
mation from each selected study. This included the fol-
lowing points: 1) Study design: study period, study
setting, and study population described by number of
eligible participants and actual number of participants;
2) Screening policy: screening procedure and sampling
sites; 3) Results: presented in the form of proportions
(expressed as the percentage of MRSA cases among
patients or among isolates of S. aureus) and density
rates (expressed as MRSA cases per 1,000 patient days).
The extraction of the data was performed by two
authors (MD, FH).
The quality of each of the included studies was assessed
by using seven criteria, taken from various checklists
aimed either at evaluating prevalence surveys [15] or at
improving the reporting of observational prevalence stu-
dies [16-19]. The criteria were expressed as questions
(Table 1). For each study, the answers to these questions
were graded as Yes if the question was satisfactorily
answered (with a score of one point), No if it was not, and
’?’ for unclear answers or missing information (with a
score of zero points). Two authors (CP, AS) independently
assessed the study quality and a third (MD) resolved dis-
crepancies. Study quality was categorized as good (> 5
points), fair (3 to 5 points) or poor (< 3 points). The cri-
teria for rating the study quality in MRSA prevalence stu-
dies and the justification for a favorable evaluation will be
described briefly.
Outcome definition
The infection-related outcome had to be clearly defined
and described for MRSA colonization and infection [18].
Definition for denominators (e.g. patients, isolates,
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ments are performed on the patient’s first admission,
these are expressed relative to the total number of
patients; if measurements are performed for each admis-
sion, these are expressed relative to the total number of
admissions. If calculations are related to isolates, it
should be stated whether only the initial MRSA isolate
or all subsequent isolates of a patient during the study
period were included. In case of multi-site swabbing, it
should be stated whether swabs were cultured separately
or as a pooled sample on the same agar plate. For den-
sity rates, it should be stated whether denominators
were adjusted for total patient days or number of
patient-days at risk for new MRSA detection [13].
Time unit
T h eo u t c o m eh a dt ob ec a l c u l a t e df o ras t a n d a r d i z e d
time unit (daily, weekly, monthly, yearly) [18].
Target population
The eligibility criteria had to be described [19].
Participants
The number of cases potentially eligible and actually
included had to be reported. A flow chart is recom-
mended for the description of the numbers and reasons
for non-participation [19].
Observer bias
A n ye f f o r t st or e d u c ep o t e n t i a ls o u r c e so fb i a sa n d
imprecision had to be described and the consequences
of any potential bias had to be discussed [18].
Screening procedure
The sampling procedures had to be described [18] and it
should be stated if swab specimens were taken by specially
trained healthcare workers [20]. Detailed instructions on
swab sampling should be given, i.e. use separate swabs for
each sampling site of the nares [5], roll the swab three
times around in the outer section of each nostril and take
the swab from the posterior wall of the throat and not
from the mouth [20]. Studies in which the sampling pro-
cedure was described in more detail and/or performed by
a staff member after appropriate training were therefore
scored with one point.
Sampling sites
The preferred screening method in MRSA prevalence
studies is to use swabs. The anterior nares are considered
to be the primary colonization site for S. aureus [1,21].
Screening of the throat in addition to nasal swabs has
increased the sensitivity of detection of S. aureus among
carriers by 20% to 26% [20,22]. Although no standards
exist for the choice of anatomical sites [4], one scoring
point was given when sampling sites included at least the
anterior nares and the throat, according to the recom-
mendations by Albrich & Harbarth [5] and various
national guidelines [12,23,24]. Studies relying on clinical
cultures in addition to screening cultures were only
awarded a point when screening cultures included sam-
ples from both the anterior nares and the throat. Surveil-
lance studies relying exclusively on clinical cultures (e.g.
blood culture of infected patients) were scored with zero
points, because clinical cultures taken for therapeutic
reasons have shown low sensitivity for detecting the
MRSA reservoir [25].
Microbiological media for MRSA screening or use of
the polymerase chain reaction were not assessed by the
quality score, as no standards exist that define the most
effective microbiological media [4].
Extracted data on study design, screening policy and
primary MRSA outcomes are described by a narrative
approach.
Results
Table 2 summarizes studies on the prevalence of MRSA in
LTC facilities. In 11 studies, surveillance data came from
the same setting, nursing homes for the elderly. Two stu-
dies (No.8,11/1) included other sectors (rehabilitation cen-
ter and hospital). The study population was recruited from
the residents of the corresponding facility. Study duration
varied between 1 and 12 months. In all 11 studies, MRSA
prevalence was derived solely from surveillance cultures.
Nasal swabs were performed in all studies, though only in
six studies by swabbing the anterior nares. In nine studies,
screening was performed as multi-site swabbing, most
Table 1 Checklist of criteria for assessing the quality of MRSA prevalence surveys
Number Name Content
1 Outcome definition Was a valid definition given of the outcome for prevalence, colonization and infection?
2 Time unit Was the endpoint calculated for a standardized time unit (daily, monthly, yearly)?
3 Target population Was the target population specified by inclusion or eligibility criteria?
4 Participants Was the number of included cases reported, e.g. by describing the numbers and reasons for non-participation?
5 Observer bias Were sources of potential imprecision reported and/or have consequences been discussed?
6 Screening procedure Were measures described that had been undertaken for standardization of screening measurements?
7 Swabbing sites Have routine surveillance cultures included the anterior nares (or nostrils or nose) and the throat?
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NO. Author
(First)
Study design Screening policy Results Quality
Rating
3
Country,
Year of
Publication
Study period,
dates
(months)
Study,
setting
(no. of
units) (n)
Basic number of
cases
potentially
eligible (n)
Study
population
(no. of
residents) (n)
Screening
methods
Swabbing
sites
Number of MRSA
patients colonised
(C) or infected (I) (n)
Proportion of MRSA
% MRSA among
patients Mean
(95% CI)
1Range
2
% MRSA among
S.aureus isolates
Mean (95% CI)
1
1 Baldwin
[36]
Northern
Ireland
2009
2005-2006 (9) NH-E (45) 1.678 1.111
4 Non-selective
on one day in
each unit
Nares, urine,
wounds,
inv.devices
267 (C) 23.3 (18.8-27.7)
Range, 0 to 73
Good
1Y; 2Y; 3Y; 4Y;
5Y; 6Y; 7N
2B a r r
[38]
UK
2007
2005 (2) Care homes
for the
elderly (39)
1.342 715
4 Non-selective Nose 159 (C) 22.0 (18.0-27.0)
Range, 0 to 50
54.0 Fair
1N; 2N; 3Y; 4Y;
5Y; 6Y; 7N
3 Baum, von
[37]
Germany
2002
1999-2000 (12) NH-E (47) 3.864 3.236
4 Non-selective Nares, skin
defects
36 (C) 1.1 (0.75-1.47)
Range, 0 to 18.2
Fair
1N; 2Y; 3Y; 4Y;
5Y; 6N; 7N
4 Brugnaro
[39]
Italy
2009
2006 (1) NH-E (2
with 15
units)
570 551
4 Non-selective
on a single day
in each unit
Nares 43 (C) 7.8 (5.7-10.4)
Range, 0 to 18
Fair
1N; 2Y; 3Y; 4Y;
5Y; 6N; 7N
5 Cretnik
[40]
Slovenia
2005
2001 (1) NH-E (1) 127 107 Non-selective Nares, skin
lesions
10 (C) 9.3 Poor
1N; 2N; 3Y; 4Y;
5N; 6?; 7N
6 Denis
[33]
Belgium
2009
2005 (9) A random
sample of
NH-E (60)
NA 2.953 Non-selective
on the same
day in each unit
Nares,
throat,
wounds,
cath. urine
587 (C) 19.5 (16.4-21.5)
Range, 2 to 42.9
39.1 Fair
1N; 2Y; 3Y; 4Y;
5Y; 6N; 7Y
7 Heuck
[41]
Germany
2000
NA NH-E (31) ? 1.342
4 Non-selective Nares,
throat,
wounds
32 (C) 2.4
Range, 0 to 2.9
6.0 Poor
1N; 2N; 3Y; 4N;
5N; 6N; 7Y
8 Heudorf
[42]
Germany
2001
1999-2000 NA NH-E (7);
geriatric RC
(1)
? NH-E: 359 RC:
42
4
Non-selective Nose, throat NH-E: 8 (C) RC: 2 (C) NH-E: 2.2 RC: 4.8 Fair
1N; 2N; 3Y; 4Y;
5Y; 6N; 7Y
9 Hoefnagels-
Schuermans
[43]
Belgium
2002
1997 (3) NH-E (17) ? 2.857 Non-selective;
one day
sampling in
each unit
Nose,
perineum
141 (C) 4.9 (4.38-6.09) 19.1 Poor
1N; 2Y; 3N; 4N;
5N; 6Y; 7N
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3Table 2 MRSA prevalence among patients and residents in long-term care facilities (Continued)
10 Neuhaus
[44]
Germany
2002
2000-2001 (12) NH-E (61) ? 1.057
4 Non-selective Nose,
throat,
wounds
32 (C) 3 (I) 3.0 (2.1-4.2) 6.3 (4.3-8.8) Fair
1Y; 2N; 3Y; 4N;
5N; 6N; 7Y
11/
1
Woltering
[45]
Germany
2008
NA (4) NH-E (5) 441 265
4 Non-selective
on a 2-days
period in each
unit
Nose,
throat,
wounds
4 (C) 2.3 (0.8-4.9) 5.9 Good
1N; 2Y; 3Y; 4Y;
5Y; 6N; 7Y
1: Pooled mean calculated as a combined prevalence rate over all units with 95% CI.
2: Range within the individual units.
3: Levels for study quality: Good (= 6 and 7 points), fair (= 3 - 5 points), poor (= 1 and 2 points). Numbers belong to the questions as illustrated in Table 1.
4: Participants who were able to give informed consent or informed consent were given by their relatives. Abbreviations: CI, Confidence intervals; N, no; NH-(E), Nursing home for the elderly; RC, Rehabilitation centre;
Y, Yes; NA, No Answer; ?, unclear or missing information.
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3often by additional swabs taken from skin lesions or
wounds. Swabbing of the throat was performed routinely
in five studies. The screening was non-selective in all stu-
dies with regard to study population. The screening proce-
dure was described in more detail in five studies (on a
single day or on a two days period in each unit). The qual-
ity level was assigned as ‘good’ in two studies, as ‘fair’ in
six studies, and as ‘poor’ in three studies. Prevalence in
LTC facilities varied from 1% to 23%, if the percentage of
MRSA among residents is taken, and from 5% to 54%, if
the percentage of MRSA among S. aureus isolates is taken.
MRSA proportions of around 20% or higher were found
in UK, Northern Ireland and Belgium.
Table 3 summarizes studies on the prevalence of
MRSA in clinical settings. A total of 20 studies were
included, of which one study presented two surveillance
approaches (No.19). Another study was considered,
which included both clinical and LTC facilities (No.11/
2). Four studies were designed as multi-center surveil-
lance studies (No.14,20,23,29). Study setting included
different forms of hospitals (university, primary or ter-
tiary care), specialized units (intensive care (ICU), sur-
gery, neurology, vascular, emergency, orthopedics),
rehabilitation centers and one laboratory facility. Study
duration varied across a range from less than 1 month
to 72 months, with accumulation round 4 months. Four
groups of study population were found: admissions (in
general or as specified admissions to ICU, to emergency,
or to geriatrics); hospitalized patients (more than 24 or
48 hours in hospital); special groups of patients (of
greater age, at discharge to home care, being a trauma
patient); and S. aureus isolates of infected patients. Iden-
tification of MRSA cases was achieved in 15 studies by
swabs for surveillance purposes exclusively, in three stu-
dies additionally by clinical cultures, and in another
three studies exclusively via clinical cultures obtained
from infected patients for therapeutic reasons.
Screening was performed at different time points: on
admission within 24 to 48 hours or during hospital stay
(one week after admission, on the 21
st day of admission,
within three days before discharge to home care, or by a
weekly screening cycle). Nasal swabbing was performed
in 18 studies, but anterior nares were used in five stu-
dies only. Wounds were the second most frequently
swabbed screening site (11 studies). Additional anatomi-
cal sites were either the throat, groin, axillae, or peri-
neum. Considering the seven quality criteria, the quality
level was assigned as ‘good’ in two studies (plus one
already counted in Table 2; No.11), as ‘fair’ in 14 stu-
dies, and as ‘poor’ in four studies.
The prevalence rates in clinical settings varied from
0.1% to 24.0% if the percentage of MRSA among
patients is taken and from 5.5% to 29.7% if the percen-
tage of MRSA among S. aureus isolates is taken. In
surveillance studies analyzing solely clinical samples of
infected patients, the percentage of MRSA among S.
aureus isolates varied between 13.8% and 21.5%
(No.20,23,29). Prevalence density was calculated in four
studies and varied between 0.4 and 0.7 MRSA-positive
cases per 1,000 patient days, when all patients gave rise
to the denominator (No.13,14,19), and was 4 MRSA iso-
lates per 1,000 patient days when calculated on the basis
of clinical samples of infected patients (No.23).
With regard to screening procedures, the MRSA per-
centage varied from less than 1% to 24% when swabs
were taken within 24 to 48 hours of admission, from
3.4% to 15.8% when swabs were taken during the hospi-
tal stay, and from less than 1% to 7.9% when swabs
were taken on admission of patients with a high risk for
MRSA carrier status. With regard to comparable clinical
settings, the MRSA percentage among patients varied
from 0.48% to 11.5% in intensive care units (n = 3),
from 7.9% to 14.6% in acute (geriatric) care wards (n =
2), from 1.6% to 24.6% in surgeries (orthopedic, trauma,
or vascular) (n = 5), from less than 1% to 15.8% for dif-
ferent wards in hospitals in general (n = 1 0), and from
1.2% to 2.1% in rehabilitation centers (n = 2).
Discussion
In this review, 31 studies on MRSA prevalence rates in
endemic situations in different healthcare settings in
eight European countries were analyzed. Prevalence
rates, defined as the proportion of MRSA-positive
patients, varied widely over a range between less than
1% and 24%. The variations in MRSA proportion were
less marked between acute-care and long-term care set-
ting, but rather between single wards in each setting.
Study quality was assessed as good in only four studies.
Most studies (n = 20) were assessed as being of fair
q u a l i t ya n ds e v e na so fp o o rq u a l i t y .T h ea i mo ft h i s
review was to present prevalence rates for endemic
MRSA in all kinds of healthcare sectors, but was not
fully achieved. In fact, MRSA rates are presented for a
few different clinical sectors and not for a variety of
LTC sectors, as in the LTC setting, surveillance was per-
formed only in nursing homes for the elderly.
In the last 10 years, significant increases in MRSA
(expressed as percentage of S. aureus blood isolates)
have been shown in European countries [3]. Time
trends for resistance proportions for MRSA have been
presented by two other surveillance systems, with an
increase of MRSA from 1% in 1990 to 20% in 2007 [26],
and stable proportions between 20% and 26% in the
years between 2001 and 2007 [27]. The MRSA rates of
the studies analyzed in this review show a different dis-
tribution, with the most frequent rates being less than
10% (expressed as MRSA among patients). The range of
MRSA rates may reflect differences in specific national
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NO. Author,
First
Study design Screening policy Results Comments Quality
rating
4
Country,
Year of
Publication
Study
period
(no. of
months)
Study
setting
1 (no.
of units) (n)
Study
population
Basic no. of
cases
potentially
eligible/no. of
participants (n)
Screening
methods
(Origin of
specimen)
Swabbing
sites
No. of MRSA
patients colonised
(C) or infected (I)
or no. of isolates
(n)
Prevalence of MRSA
% MRSA
among
patients
Mean
2
(95% CI)
Range
3
% MRSA
among S.
aureus
isolates
Mean
2
Density (no.
of MRSA
per 1,000
patients
days
12 Chaberny
[46]
Germany
2008
2005
(<1)
ICU (1),
surgery (1),
neurology (1),
internal
medicine (1)
Patients 700/509 On a given
study day
Nares, throat,
skin lesions
27 (C) 5.3 (3.5-7.7)
ICU: 11.5
a
Surgery: 5.5
a
Neuro. 11.8
Int. med.: 5.1
19.0
a Units with
established
admission
screening
Good
1Y; 2Y;
3Y; 4Y;
5Y; 6Y;
7Y
13 Chaberny
[47]
Germany
2005
2002
(12)
ICU (4) Admissions ?/188.615 On
admission
of patients
at risk for
MRSA
Clinical
samples
5
n.r. 505 (C) 404 (I) 0.48 0.64
a
0.29
a,b
a
Admissions
b Noso-
comial
Fair
1Y; 2Y;
3N; 4Y;
5N; 6Y;
7?
14 Chaberny
[7]
Germany
2007
2004
(12)
Hospital (31) Hospita-lized
patients
?/660.042 During
hospital
stay
Clinical
samples
5
Nares 2.786 (C) 1.429 (I) 0.71
a
0.27
a,b
a
Admissions
b Noso-
comial
Fair
1Y; 2Y;
3Y; 4N;
5Y; 6N;
7N
15 Eveillard
[48]
France
2002
2000 (1) Acute geriatric
ward (2)
Patients 244/239 On the first
day of
admission
Nares,
wounds
35 (C) 14.6 (10.1-
19.1)
Fair
1N; 2Y;
3Y; 4Y;
5N; 6N;
7N
16 Anonymous
[49]
Germany
2010
2008 (1) RC (6), GH (8) Patients ?/6.985 On
admission
during
initial exa-
mination
Nose,
throat
95 (C) RC: 2.1
GH: 1.2
RC: 9.4
GH: 5.5
Fair
1N; 2Y;
3Y; 4N;
5N; 6?;
7Y
17 Hassan
[50]
Ireland
2008
2005 (3) Orthopedic
ward (2)
Patients 690/686 Within 24
hrs of
admission
Nose,
perineum,
surgical
wounds
27 (C) 3.9 Fair
1N; 2N;
3Y; 4Y;
5N; 6Y;
7N
18 Hori
[14]
UK
2002
2000 (4) UH (1) Patients older
than 64 years
431/342 On the
21
st day
after
admission
Nares 54 (C) 15.8 Fair
1N; 2Y;
3Y; 4Y;
5Y; 6N;
7N
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3Table 3 MRSA prevalence among patients in clinical settings (Continued)
19/
1
Kappstein
[51]
Germany
2009
2000-
2005
(72)
UH (1) Patients ? On
admission
Clinical
samples
5
Nose 489 (C) 38 (I) 0.42 Poor
1Y; 2N;
3N; 4N;
5N; 6N;
7N
19/
2
Kappstein
[51]
Germany
2009
2002-
2005
(42)
UH (1) Patients 141.249/29.692 Within
48 hrs of
admission
Nose,
wounds
231 (C) 0.78
20 Kresken
[26]
Germany
2009
2007
(1)
LF (26) S. aureus
isolates
?/872 Clinical
samples
5
159 isolates 20.3 Poor
1N; 2Y;
3Y; 4N;
5N; 6N;
7N
21 Lucet
[52]
France
2009
2003-
2004
(14)
Hospitals for
primary and
tertiary care
(16)
Patients at
discharge to
home care, >
48 hrs in
hospital
a
2.025/1.501 Within
3 days
before
discharge
Nose,
chronic skin
lesions
191 (C) 12.7
(11.0-14.5)
a Obstetric
patients
excluded
Fair
1Y; 2N;
3Y; 4Y;
5Y; 6Y;
7N
22 Lucet
[53]
France
2005
2002
(3,5)
Acute care
ward in a
hospital (1)
Patients older
than 75 years,
> 24 hrs in
hospital
1.434/797 Within 48
hrs of
admission
Nose,
skin breaks
63 (C) 7.9
a
(6.0-9.8)
29.7
aa
Admissions
Fair
1Y; 2N;
3Y; 4Y;
5Y; 6Y;
7N
23 Meyer
[54]
Germany
2006
2001-
2004
(48)
ICU (40) S. aureus
isolates of
patients with
noso-comial
infections
?/12.238 Clinical
samples
5
2.631 isolates 21.5 4.4 Good
1Y; 2Y;
3Y; 4Y;
Y5; 6N;
7N
24 Morange-
Saussier
[55]
France
2006
2004
(4)
Vascular
surgery (1)
Patients,
> 24 hrs in
hospital
?/308 On
admission
and 1 wk
thereafter
Nares 13 (C) 4.2 27.0 Fair
1Y; 2Y;
3Y; 4Y;
5N; 6N;
7N
25 Gopal Rao
[29]
UK
2007
2004-
2005
(12)
GH (1);
emergency
department
Adult
emergency
admissions
13.826/7.801 Prior to
admission
Nose,
axillae
670 (C)
433 (C)
8.6
a
6.7
b
a
Admissions
b Patients
Fair
1N; 2Y;
3Y; 4Y;
5Y; 6N;
7N
26 Reilly
[56]
UK
2010
2008
(5)
GH (6) Emergency
(68%) and
elective (32%)
admissions
29.690/26.160 On
admission
or at pre-
admission
(7.5%)
Nose,
wounds,
invasive
device sites
988 (C+I) 3.8
a
(3.5-4.0)
a
Admissions
Fair
1N; 2N;
3Y; 4Y;
5Y; 6Y;
7N
27 Tai
[57]
UK
2004
2000
(12)
Orthopedic
and trauma
surgery (1)
Patients
at high risk for
MRSA
1.879/121 On
admission
Clinical
samples
5
Nose, throat,
axillae,
groins,
wounds
10 (C)
21 (I)
1.6 Poor
1Y; 2N;
3Y; 4N;
5N; 6N;
7N
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28 Thompson
[58]
UK
2004
2001-
2004
(30)
ICU (1) Admissions to
ICU
1.472/1.361 On
admission
Weekly
screening
cycle
Clinical
samples
5
Nose, groins 119 (C+I)
68 (C+I)
b
8.7
a (6.1-
10.2)
a
Admissions
b
Nosocomial
Incidence:
1
st wk:
7.5%; 2
nd to
4
th wk:
20.3%
Fair
1Y; 2?;
3Y; 4?;
5Y; 6N;
7N
29 Tiemersma
[3]
Germany
2004
1999-
2002
(36)
Hospitals (25) S. aureus
blood isolates
?/3.757 Blood
cultures
5
600 isolates 13.8 Poor
1Y; 2?;
3N; 4Y;
5N; 6N;
7N
30 Vos
[59]
NL
2009
2000-
2004
(60)
UH (1) Admissions
at high risk for
MRSA
?/
21.598
On
admission
Nose, throat,
perineum,
invasive
devices,
wounds
123 (C) 0.10 0.0028
aa Related to
bacteremia
cases
Fair
1N; 2Y;
3Y; 4N;
5Y; 6N;
7Y
31 Walley
[60]
UK
2009
2003
(3)
Trauma and
ortho-pedic
ward (1)
Elective and
trauma
patients,
> 48 hrs in
hospital
559/323 Within 24-
48 hrs of
admission
Nose,
perineum
78 (C) 24.0 Fair
1Y; 2N;
3Y; 4Y;
5Y; 6?;
7N
11/
2
Woltering
[45]
Germany
2008
GH (5),
RC (3)
Patients 1.321/818 On
a 2-days
screening
period in
each unit
Nose, throat,
wounds
GH: 17 (C)
RC: 6 (C)
GH: 3.4
(2.1-5.6)
RC: 1.2
(0.4-3.3)
GH: 11.6
RC: 5.6
Good
1N; 2Y;
3Y; 4Y;
5Y; 6N;
7Y
1: UH = University hospital, ICU = Intensive care unit, TH = Teaching hospital, GH = General hospital, RC = Rehabilitation centre, LF = Laboratory facility, n.r. = not reported.
2: Pooled mean calculated as a combined prevalence rate over all units with 95% CI.
3: Range within the individual units.
4: Levels for study quality: Good (= 6 and 7 points), fair (= 3 - 5 points), poor (= 1 and 2 points). Numbers belong to the questions as illustrated in Table 1.
5: Specimens (blood, sputum, others) taken for diagnostic purposes. Abbreviations: CI, Confidence intervals; hrs, hours; N, no; wk, week; Y, Yes; ?, unclear or missing information.
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3characteristics (countries with known higher MRSA
rates), but may also be caused by methodological weak-
nesses, as seen by the quality of the included studies.
Interpretation of the results is most hampered by the
heterogeneity in the study population, screening policy,
study period, and calculation of the outcome.
Study population
As study participants were not homogenous, but were
members of different populations (admissions, patients,
residents, and S. aureus isolates), it was difficult to com-
pare MRSA rates. In the clinical setting, inclusion criteria
were time-related (on admission or during hospital stay)
and risk-related (patients with a high risk for MRSA car-
rier status). Regardless of the different inclusion criteria,
all studies are prone to underestimate the MRSA reservoir.
Admission-only screening does not assess healthcare-asso-
ciated transmission [13], but rather provides data on
imported MRSA cases [28], although transmission of
MRSA in most cases happened during a previous hospital
stay. Selective screening of high-risk patients on admission
to the hospital or to special wards is a strategy recom-
mended by national guidelines, but risk factors for MRSA
carriage are not standardized, nor were they described by
the studies. In addition, poor compliance with selective
risk factor based screening has been reported [29], so that
not all colonized patients may have been detected. In the
case of screening programs including only groups of high-
risk patients after admission to hospital, MRSA rates are
not representative for the hospitalized population as a
whole [13,14]. Underestimation of the MRSA reservoir is
also expected from studies relying exclusively on clinical
cultures taken for therapeutic reasons, as they may fail to
identify 85% of the MRSA-colonized patients [25].
In the LTC setting, even if all study participants were
recruited as residents of nursing homes for the elderly,
comparison of the MRSA rates is difficult, because poten-
tially eligible cases were not described by inclusion criteria.
The findings of this review suggest that screening programs
in LTC facilities are not assigned to admission of new resi-
dents. However, time-points for screening were used in
some studies in an almost standardized way (No.1,4,6,9,11),
so that these rates may present representative rates for the
population of residents in the nursing home as a whole.
No statement is possible for endemic MRSA in LTC set-
tings such as home care, day-care institutions for (multiply)
handicapped people, or institutions for patients with long-
term artificial respiration. Only one study (No.21) investi-
gated the MRSA clearance on discharge from hospital of
home-care patients colonized with MRSA.
Screening policy
Swabs were the preferred screening method in the
included studies, but heterogeneity was found for the
anatomical sites which had been swabbed. Even though
the contribution of variations in sampling procedures is
not clear [30], lack of sensitivity of the swabbing sites has
to be considered when surveillance data from different
facilities are compared [31]. For the studies using only
nasal swabs, underreporting of MRSA cases is suggested,
given that cultures of the nares identify only 60%-73% of
the S. aureus carriers [20,22,31,32]. That is why in national
guidelines screening of additional sites is recommended,
though no consensus has been reached [4,31]. For reasons
of accessibility, compliance and consistency with other
investigations, it is recommended by Hori [14] that the
investigation of MRSA prevalence should be confined to
nasal swabs. Though this recommendation might be con-
sidered excessively strict, it is nevertheless reasonable, as it
permits comparison between different studies.
The swabbing procedure is described in more detail in
only a very few studies. Therefore, difference in swab-
bing procedures might also be a reason for the different
MRSA rates. For standardization of MRSA measurement
by surveillance cultures, the sampling procedures have
to be considered [4] and it is recommended that the
swab specimens are obtained only by specially trained
healthcare workers [20].
Study period
The range in study period, between less than one
months and six years, is due to the two most often used
screening modes, point prevalence and prospective
screening over different study phases. As the data were
generally related to total study period, results are not
comparable. According to the ORION statement, infec-
tion-related outcomes should be related to regular time
units rather than presented as totals for study phase
[18]. There are no standards for the most effective
screening mode for MRSA prevalence. Even if point-
prevalence rates offer the best choice for comparison,
the limitations of this method should be kept in mind,
as with point-prevalence onl yas h o r t - t i m ec u t - o u ti s
considered and prevalence on another day might differ
[33]. Repeated point-prevalence measurements are
therefore recommended in order to achieve a more
comprehensive view of the endemic situation [34].
Calculation of the outcome
Comparison of MRSA rates was hampered, as two dif-
ferent prevalence numerators were used, patients colo-
nized with MRSA and methicillin-resistant isolates. A
further difficulty was that the method of counting dif-
fered with regard to repeated admission or repeated
MRSA-findings of a patient during the study period,
which complicates the comparison.
Comparison of MRSA rates was also hampered, by the
fact that the outcomes were reported either in the form
Dulon et al. BMC Infectious Diseases 2011, 11:138
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Page 10 of 13of proportions or as prevalence density. For resistance
proportions (expressed as MRSA among S. aureus iso-
lates), consistency was observed for the clinical setting
(between 13% and 20%), but these data are not available
for the LTC setting. From a public health perspective,
resistance proportions do not allow an unbiased esti-
mate of the MRSA burden in the respective setting [35],
and therefore density rates are recommended as a more
appropriate measure for the average MRSA burden
[7,27]. MRSA rates in the form of density data were pre-
sented by only a few studies. As most studies mislead-
ingly reported incidence density using total patient days
as denominators (instead of patient days at risk for new
MRSA detection), the true incidence of MRSA acquisi-
tion is probably underestimated [13]. Concerning the
differences in calculations of MRSA outcomes, the find-
ings of our review are in line with the assessment of
other authors, that up to now no surveillance method
allowing calculation of the rate of MRSA colonization
and infection has been gained acceptance as a valid
method for comparisons between institutions [7].
One of the limitations in our review is that a high
proportion of the retrieved articles was excluded from
the review, as MRSA prevalence was not the primary
objective. Inflation of MRSA hits is probably caused by
a trend to add MRSA to both keyword lists and
abstracts of every study of even peripheral relevance to
the surveillance of antimicrobial resistance. Another lim-
itation in our review is that the quality of the studies
was not assessed by a validated score. However, the
majority of the selected quality criteria have already
been used to critically appraise research articles which
estimate the prevalence of a disease [15].
Conclusions
Since the recognition of MRSA as a hospital problem
largely depends on swabs or clinical samples taken on
admission or during hospital-stay of high-risk patients,
t h et r u ec a s el o a do fah o s p i t a lr e m a i n sl a r g e l y
unknown. In order to enable comparison between differ-
ent studies and different settings, MRSA rates should be
assessed in a standardized way, e.g. the anterior nares
should always be included and sampling should be per-
formed by a trained person.
Accurate incidence measures using denominator data
adjusted for the at-risk population are warranted for
comparing MRSA studies. However, these incidence
measures are difficult to obtain, especially in LTC set-
tings. Therefore less demanding estimates of MRSA
r a t e ss h o u l db eu s e di nas t a n d a r d i z e dw a yi nc l i n i c a l
and LTC settings in order to allow comparison. Consen-
sus should be achieved, in order to define standardized
procedures for MRSA surveillance in different health-
care settings.
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